List of Excipients in Branded Drug PANCREAZE

« Back to Dashboard

PANCREAZE Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

PANCREAZE is a delayed-release pancrelipase product whose commercial performance depends on enzyme stability, enteric protection, dose flexibility, and reliable delivery with food. The main excipient opportunity is not a simple capsule substitution. It is the development of bead-coating, moisture-control, capsule, and sprinkle-delivery systems that preserve lipase activity and meet FDA requirements for complex enzyme products.

PANCREAZE contains porcine-derived lipase, amylase, and protease in enteric-coated beads. Its labeled strengths are 4,200, 10,500, 16,800, and 21,000 USP units of lipase per capsule. The product is approved for exocrine pancreatic insufficiency associated with cystic fibrosis, chronic pancreatitis, and pancreatectomy. [1]

What excipients are used in PANCREAZE?

PANCREAZE uses excipients in two functional groups: bead-core and coating materials, and capsule-shell components.

Formulation element	Functional role	Commercial relevance
Microcrystalline cellulose	Bead substrate, filler, and mechanical support	Supports pellet manufacture and dose uniformity
Croscarmellose sodium	Disintegrant and matrix modifier	Helps the bead core disperse after enteric-coating failure at higher intestinal pH
Colloidal silicon dioxide	Flow aid and moisture-control support	Improves powder and bead handling
Magnesium stearate	Lubricant	Supports encapsulation and manufacturing throughput
Enteric-coating system	Protects enzymes from gastric acid	The highest-value excipient function in the product
Gelatin capsule shell	Immediate dosage-form enclosure	Enables swallowing and opening for sprinkle administration
Titanium dioxide and colorants	Opacity and strength identification	Creates potential demand for color-free or simplified shells
Printing ink	Product identification	Supports strength differentiation and anti-counterfeit controls

The FDA prescribing information identifies inactive ingredients by product component and strength. The precise capsule colors and printing materials can vary by strength and market presentation. [1]

The key technical feature is the enteric-coated bead. Pancrelipase enzymes are vulnerable to gastric acid and must be released in the duodenum or proximal small intestine. Excipients therefore affect therapeutic performance through acid resistance, coating permeability, dissolution pH, enzyme stability, bead size, and dispersion.

How does the PANCREAZE delayed-release system work?

PANCREAZE capsules release enteric-coated beads after the capsule shell dissolves. The beads are designed to resist gastric conditions and release enzyme at a higher intestinal pH.

A commercially viable bead system must control four variables:

1. Gastric acid protection.
2. Release onset in the small intestine.
3. Enzyme activity after processing and storage.
4. Uniform distribution of lipase, amylase, and protease across beads and capsules.

The excipient strategy is therefore inseparable from process design. The same polymer system can produce materially different performance depending on spray rate, coating weight gain, curing conditions, residual moisture, bead porosity, and enzyme exposure to heat or solvents.

Which coating polymers are relevant?

Potential enteric systems include methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, and related aqueous or organic-solvent coating platforms. Commercial development generally favors aqueous methacrylate or cellulose-based systems because they offer scalable processing and established pharmaceutical use.

For PANCREAZE-type products, the coating must balance acid resistance against timely release. Excessive coating thickness can delay enzyme delivery, while insufficient coating can cause premature release and loss of activity in the stomach.

Plasticizers, anti-tacking agents, pore-forming agents, and subcoats can materially change dissolution. Talc, colloidal silica, triethyl citrate, polyethylene glycol, and related materials may be evaluated during formulation development, although the selected composition must be validated against the reference product’s performance.

What excipient opportunities exist for PANCREAZE competitors?

The strongest opportunities are in performance-enhancing excipient systems rather than commodity fillers.

Enteric-coating optimization

Excipient suppliers can target:

• Lower coating weight with equivalent acid resistance.
• Faster and more reproducible intestinal release.
• Reduced enzyme denaturation during coating.
• Aqueous coating systems with lower solvent and containment requirements.
• Lower tackiness and improved bead yield.
• More consistent performance across commercial-scale batches.

A coating platform that improves enzyme retention while reducing processing time could create value for generic or follow-on pancrelipase manufacturers.

Moisture and stability control

Pancrelipase is sensitive to environmental conditions. Moisture exposure can affect enzyme activity, bead integrity, capsule behavior, and dissolution. Commercial opportunities include:

• High-barrier blister packaging.
• Desiccant-integrated bottles.
• Low-moisture capsule shells.
• Moisture-scavenging excipient systems.
• Improved seal coats between the enzyme-containing core and enteric layer.
• Stability-indicating packaging configurations.

Packaging is not technically an excipient, but it is part of the same commercial control strategy. A formulation that performs well only under tight humidity conditions may have limited market value.

Capsule-shell alternatives

PANCREAZE uses hard capsules. Potential alternatives include:

• Hypromellose capsules.
• Pullulan capsules.
• Low-moisture gelatin capsules.
• Color-free shells.
• Titanium-dioxide-free shells.
• Capsules optimized for opening and sprinkling.

A capsule-shell change can improve patient acceptability and address regulatory or consumer pressure against certain colorants. It can also introduce new problems, including altered moisture transfer, brittleness, swelling, and interaction with enteric-coated beads.

Sprinkle and pediatric delivery

Patients may open PANCREAZE capsules and sprinkle the contents on acidic soft foods, subject to label instructions. The beads must remain intact during handling and must not be chewed. This creates a meaningful excipient opportunity for:

• Better bead size uniformity.
• Reduced mouthfeel and grittiness.
• Improved adhesion to soft food without premature release.
• Reduced bead breakage during capsule opening.
• Pediatric-friendly capsule shells.
• Dose-flexible multiparticulate packaging.

Any change that affects bead size, coating strength, release, or food compatibility would require comparative performance data.

What regulatory requirements apply to PANCREAZE excipients?

FDA treats pancreatic enzyme replacement therapies as complex products. The active ingredient is a mixture of enzymes rather than a single chemically defined molecule. The regulatory assessment therefore extends beyond conventional composition and assay.

FDA’s guidance identifies several critical quality attributes for pancrelipase products, including enzyme identity, potency, purity, stability, dissolution, and manufacturing consistency. [2]

A follow-on product must address:

Regulatory issue	Impact on excipient strategy
Complex active mixture	Excipient changes can alter enzyme stability and activity
Delayed-release performance	Coating composition and process parameters are critical
Multiple enzyme activities	Lipase, amylase, and protease may respond differently to processing
Food-dependent administration	Product performance must remain clinically useful with meals and snacks
Sprinkle administration	Bead integrity and food compatibility require characterization
Batch variability	Supplier changes and coating-process changes require comparability work
Stability	Moisture, temperature, and packaging must be controlled
Therapeutic equivalence	Dissolution and in vivo performance are central to approval

The FDA’s 2006 guidance established the framework for bringing unapproved pancreatic enzyme products into compliance. Later regulatory practice has focused on manufacturing controls and product-specific evidence rather than relying only on chemical equivalence. [2]

What is the Orange Book status of PANCREAZE?

PANCREAZE is approved under NDA 022210. The FDA Orange Book is the relevant source for current patent listings, exclusivity information, and therapeutic-equivalence codes. [3]

Unlike a conventional small-molecule tablet, PANCREAZE’s competitive protection is likely to depend heavily on formulation know-how, manufacturing process control, clinical evidence, and regulatory complexity. Publicly visible patent protection should be assessed separately from commercial barriers because a product may remain difficult to replicate even when Orange Book patent coverage is limited.

Protection layer	Relevance to PANCREAZE
Orange Book patents	Can delay or complicate ANDA approval if listed and enforceable
Regulatory exclusivity	May restrict approval during the statutory exclusivity period
Enteric-coating know-how	Can create practical development barriers
Enzyme sourcing	Porcine tissue sourcing and purification affect supply
Manufacturing scale-up	Pelletization and coating reproducibility are difficult
Clinical and dissolution data	Supports approval and can raise development costs
Brand familiarity	Influences prescriber and patient retention

The FDA’s current Orange Book listing should control any patent-expiration analysis. Patent expiry cannot be inferred from the original 2010 approval date alone.

When does PANCREAZE lose exclusivity?

PANCREAZE’s regulatory exclusivity is separate from patent protection. A three-year period of marketing exclusivity may apply to certain approved changes supported by new clinical investigations, but that period does not create a permanent barrier to abbreviated approval. [3]

The more significant commercial question is whether a competing pancrelipase product can establish therapeutic equivalence and obtain an AB rating. For complex enzyme products, market entry can be delayed by:

• Product-specific FDA requirements.
• Difficulty reproducing enzyme potency.
• Delayed-release dissolution differences.
• Need for comparative clinical or pharmacodynamic evidence.
• Patent litigation under Paragraph IV.
• Manufacturing and sourcing constraints.

A generic applicant may submit a Paragraph IV certification if it asserts that a listed patent is invalid, unenforceable, or not infringed. The reference-product sponsor can respond with patent litigation, potentially triggering a 30-month stay under the Hatch-Waxman framework. [4]

Which companies compete with PANCREAZE?

PANCREAZE competes primarily with other pancreatic enzyme replacement therapies rather than with ordinary oral solid-dose products.

Product	Active ingredient	Major commercial distinction
PANCREAZE	Pancrelipase	Delayed-release enteric-coated beads
CREON	Pancrelipase	Broad strength range and established brand presence
ZENPEP	Pancrelipase	Delayed-release capsule and sprinkle administration
PERTZYE	Pancrelipase	Delayed-release capsules with distinct formulation and labeling
Generically approved pancrelipase products	Pancrelipase	Potential price competition subject to FDA approval and equivalence

CREON is the largest and most visible benchmark in the category. ZENPEP and PERTZYE compete through product availability, dosing flexibility, payer access, and prescriber familiarity. The principal competitive variable is not the identity of the enzyme mixture, which is broadly similar, but delivery performance, pricing, supply reliability, and reimbursement.

How strong is the PANCREAZE patent estate?

The practical strength of the PANCREAZE estate depends on three components:

1. Current Orange Book listings.
2. Unlisted formulation and process patents.
3. Manufacturing know-how that is difficult to reproduce from public disclosures.

Formulation patents may cover bead composition, enteric polymers, coating levels, stabilizers, particle-size distributions, and release profiles. Method-of-use patents may cover dosing in cystic fibrosis, chronic pancreatitis, pancreatectomy, or specific food-related administration practices.

A narrow coating patent may have limited blocking value if a competitor can use a different polymer or process. A broader patent covering a defined delayed-release profile, enzyme stabilization system, or multiparticulate architecture may create greater risk for a follow-on product.

What generic entry risks exist for PANCREAZE?

The highest-risk launch scenario is a follow-on product with:

• Equivalent enzyme activities.
• Similar delayed-release dissolution.
• Stable activity under labeled storage conditions.
• Comparable administration with food.
• Capsule-opening and sprinkle performance.
• Acceptable payer substitution.
• No unresolved Paragraph IV litigation.

Excipient substitutions create both opportunity and risk. A new polymer, capsule shell, lubricant, or moisture-control system may avoid a formulation patent, but it can also alter dissolution or enzyme activity enough to create regulatory or clinical problems.

The most commercially attractive development path is a differentiated equivalent with a robust coating process, lower manufacturing cost, improved storage stability, and a patient-friendly capsule or sprinkle presentation.

What licensing deals could create value?

Potential licensing targets include:

• Enteric-polymer systems with documented enzyme compatibility.
• Multiparticulate coating platforms.
• Low-moisture or vegetarian capsule technology.
• Enzyme stabilization excipients.
• High-barrier packaging.
• Contract development and manufacturing capacity for enzyme pellets.
• Regional rights for pancrelipase products.
• Formulation patents covering alternative bead architectures.

A licensing agreement is most valuable when it combines composition rights with manufacturing know-how. A standalone excipient license may have limited leverage if the licensee still lacks a validated pelletization and coating process.

What are the main commercial opportunities?

The commercial opportunity is strongest in five areas:

1. Generic or follow-on pancrelipase development.
2. Excipient supply for enteric-coated enzyme beads.
3. Contract manufacturing of coated multiparticulates.
4. Pediatric and sprinkle-friendly dosage forms.
5. Packaging and stability systems that improve shelf life and distribution.

Revenue exposure is concentrated in chronic-use patients. Pancreatic enzyme replacement is taken with meals and snacks, creating recurring prescription demand. Products that improve adherence, simplify dose titration, or reduce out-of-pocket cost can compete even without a major pharmacological difference.

Key Takeaways

• PANCREAZE is a delayed-release pancrelipase product built around enteric-coated beads.
• The highest-value excipient function is protection of enzymes from gastric acid while enabling timely intestinal release.
• Enteric polymers, plasticizers, moisture-control systems, capsule shells, and bead substrates are the main development targets.
• Generic entry is difficult because pancrelipase is a complex enzyme mixture with demanding potency, dissolution, stability, and manufacturing requirements.
• Orange Book patents, regulatory exclusivity, formulation patents, process know-how, and supply controls must be analyzed separately.
• The strongest commercial opportunity is a stable, scalable, cost-efficient multiparticulate formulation with reliable sprinkle performance.
• PANCREAZE competes with CREON, ZENPEP, PERTZYE, and future generic pancrelipase products.
• Current patent and exclusivity conclusions should be based on the live FDA Orange Book and applicable litigation records.

FAQs

Can PANCREAZE capsules be reformulated with hypromellose shells?

Yes, but the shell change would require evaluation of moisture transfer, capsule dissolution, bead stability, storage performance, and administration by opening and sprinkling. It would not be a simple inactive-ingredient substitution.

Which excipient has the greatest effect on pancrelipase performance?

The enteric-coating system generally has the greatest effect because it controls acid resistance and intestinal release. Coating thickness, polymer grade, plasticizer level, and curing conditions can all change performance.

Can a competitor avoid PANCREAZE patents by changing the enteric polymer?

Potentially, but a polymer change may not avoid patents covering release profiles, bead architecture, coating thickness, process conditions, or enzyme stabilization. It also requires comparative dissolution and stability evidence.

Is PANCREAZE interchangeable with CREON?

Interchangeability depends on FDA therapeutic-equivalence determinations and the applicable product listing. Similar active ingredients do not by themselves establish automatic pharmacy substitution.

Are porcine-free PANCREAZE alternatives commercially feasible?

A porcine-free alternative would require a different enzyme source and a separate regulatory and clinical strategy. The technical challenge includes matching lipase, amylase, and protease activity, stability, purity, and clinical performance.

References

1. U.S. Food and Drug Administration. (n.d.). PANCREAZE (pancrelipase) delayed-release capsules prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2006). Guidance for industry: Exocrine pancreatic insufficiency drug products: Submitting NDAs. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. Center for Drug Evaluation and Research.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355.